CLAIMS

1. Use of an antiviral agent comprising acyclovir or a salt or solvate thereof, or valacyclovir or a salt or solvate thereof, or famciclovir or a salt or solvate thereof or combinations thereof in the preparation of a medicament for pre-exposure prophylaxis against herpes simplex virus (HSV) infection in an HSV seronegative subject in need thereof, in which the medicament comprises a therapeutically effective amount of 0.5 mg/kg body weight to about 100 mg/kg body weight, and in which the medicament is to be orally administered to the subject daily to reduce HSV infection in the subject.

2. Use according to Claim 1, in which the antiviral agent comprises valacyclovir or a salt or solvate thereof.

3. Use according to Claim 1, in which the antiviral agent comprises famciclovir or a salt or solvate thereof.

4. Use according to Claim 1, in which the antiviral agent comprises acyclovir or a salt or solvate thereof.

5. Use according to Claim 1, in which the antiviral agent comprises valacyclovir or a salt or solvate thereof and famciclovir or a salt or solvate thereof.

6. Use according to Claim 1, in which an effective amount of a contraceptive is to be further administered to the subject.

7. Use according to Claim 1, in which the medicament is to be administered prior to physical contact with a partner who is seropositive for HSV.

8. Use according to Claim 7, in which a medicament comprising a therapeutically effective amount of 0.5 mg/kg body weight to about 100 mg/kg body weight of an antiviral agent comprising acyclovir or a salt or solvate thereof, or valacyclovir or a salt or solvate thereof, or famciclovir or a salt or solvate thereof, or combinations thereof is to be administered to the HSV seropositive partner.

9. Use according to Claim 1, in which the antiviral agent comprises a sustained-release form.

10. Use according to Claim 7, in which the antiviral agent comprises a sustained-release form.

11. Use according to Claim 1, in which a therapeutically effective amount of an HIV antiviral agent is to be administered to the subject for preventing HIV infection.

12. Use according to Claim 1, in which an effective amount of a contraceptive is to be administered to the subject, in which the subject is female, for preventing conception.

13. Use according to Claim 12, in which the contraceptive is an emergency contraceptive.

14. Use according to Claim 11 in which the medicament is to be administered before physical contact with a partner who is seropositive for HIV and/or HSV.

15. Use according to Claim 14, in which the subject is seronegative for HIV.

16. Use according to Claim 14, in which the HSV seronegative subject is seropositive for HIV.

17. Use according to Claim 1, in which the antiviral agent comprises famciclovir and valacyclovir.

18. Use according to Claim 7, in which the antiviral agent comprises famciclovir and valacyclovir.

19. Use according to Claim 1 or 7, in which an adjuvant is to be administered to the subject.

20. Use according to Claim 1, 7 or 14, in which the therapeutically effective amount of the antiviral agent is from about 5 mg to about 2000 mg.

21. Use according to Claim 1, 7 or 14, in which the therapeutically effective amount of valacyclovir is a daily dosage of about 200 mg to about 2500 mg.

22. Use according to Claim 1, 7 or 14, in which the therapeutically effective amount of acyclovir is a daily dosage of about 200 mg to about 2000 mg.

23. Use according to Claim 1, 7 or 14, in which the therapeutically effective amount of famciclovir is a daily dosage of about 400 mg to about 1000 mg.

24. Use according to Claim 1 or 7, in which the HSV is HSV-1 or HSV-2.